See more : Lianhua Supermarket Holdings Co., Ltd. (LHUAF) Income Statement Analysis – Financial Results
Complete financial analysis of Intelligent Bio Solutions Inc. (INBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intelligent Bio Solutions Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Pan Asia Chemical Co. (4707.TWO) Income Statement Analysis – Financial Results
- Olam Group Limited (OLMIY) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (JPM-PK) Income Statement Analysis – Financial Results
- Runway Growth Finance Corp. (RWAY) Income Statement Analysis – Financial Results
- Brambles Limited (BMBLF) Income Statement Analysis – Financial Results
Intelligent Bio Solutions Inc. (INBS)
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.69M | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 45.81% | 25.99% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.67M | 507.42K | 3.85M | 4.27M | 588.21K | 3.18M | 2.53M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 139.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K |
| SG&A | 9.26M | 8.03M | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 173.00K |
| Other Expenses | 776.50K | 0.00 | -437.15K | -947.41K | -188.74K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 8.76M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Cost & Expenses | 13.39M | 9.69M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Interest Income | 84.82K | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 | 151.28K |
| Interest Expense | 167.14K | 223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K | 0.00 |
| Depreciation & Amortization | 1.20M | 966.73K | 8.34M | 5.21M | 2.60M | 5.83M | 4.60M | 188.72K |
| EBITDA | -8.81M | -9.47M | 30.83K | -1.82M | -561.19K | -1.50M | -416.92K | -151.28K |
| EBITDA Ratio | -283.14% | -593.55% | 0.00% | -361.23% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | -6.73M | -4.60M | -173.00K |
| Operating Income Ratio | -330.46% | -1,002.11% | 0.00% | -281.42% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 92.24K | 1.93M | 2.90K | -1.71M | -457.75K | -664.84K | -453.31K | -138.67K |
| Income Before Tax | -10.19M | -10.66M | -8.33M | -8.52M | -3.16M | -7.39M | -5.06M | -311.67K |
| Income Before Tax Ratio | -327.50% | -848.50% | 0.00% | -430.15% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 190.70K | -27.93K | 2.50M | 550.26K | -57.69K | -36.39K | -167.01K |
| Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M | -7.34M | -5.02M | -340.01K |
| Net Income Ratio | -326.40% | -845.89% | 0.00% | -355.33% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| EPS | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| EPS Diluted | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| Weighted Avg Shares Out | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
| Weighted Avg Shares Out (Dil) | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders...
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results
- Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023 - - Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended...
Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates
Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint sweat-based drug testing
Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions' Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees
Intelligent Fingerprinting to be used for in-house drug testing, enabling full testing control to support new James Jones drug and alcohol testing policy
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-12 reverse split of its...
DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing
Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors
UK's largest independent chemical manufacturer takes drug testing in-house with Intelligent Fingerprinting Drug Screening System
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Robinson Brothers, one of the UK's largest independent chemical...
Intelligent Bio Solutions Receives NATA Accreditation for its Revolutionary Fingerprint Sweat Drug Screening System
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has received National Association of Testing Authorities (NATA) accreditation for...
Leading Pan-European Ferry and Logistics Company, P&O Ferries, Adopts Fingerprint Drug Screening Solution for On-Board, Random Testing of Seafaring Staff
Intelligent Fingerprinting Drug Screening System is expected to reduce P&O Ferries' overall drug testing costs by 90%
Leading Specialist Material Handling Company, Titan Cranes and Rigging Pty Ltd., Adopts Intelligent Fingerprinting Drug Screening System
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Titan Cranes and Rigging Pty Ltd. ("Titan") has adopted...
Source: https://incomestatements.info
Category: Stock Reports